Cargando...
Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study
BACKGROUND: It is crucial to determine whether infliximab (IFX) therapy could be safely interrupted in Crohn’s disease (CD) patients with clinical remission. The outcome and risk predictors of relapse after IFX therapy stopped are controversial. The aim was to assess the relapse and predictive facto...
Guardado en:
| Publicado en: | Gastroenterology Res |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Elmer Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412541/ https://ncbi.nlm.nih.gov/pubmed/28496529 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/gr800w |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|